154 related articles for article (PubMed ID: 38352847)
41. Novel PARP7 Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2023 Dec; 14(12):1615-1616. PubMed ID: 38116422
[TBL] [Abstract][Full Text] [Related]
42. Novel PARP1 Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2023 Dec; 14(12):1629-1630. PubMed ID: 38116419
[TBL] [Abstract][Full Text] [Related]
43. Novel ACC Inhibitors for Treating Acne.
Sabnis RW
ACS Med Chem Lett; 2024 Apr; 15(4):445-446. PubMed ID: 38628789
[TBL] [Abstract][Full Text] [Related]
44. Novel CD73 Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2024 May; 15(5):571-572. PubMed ID: 38746902
[TBL] [Abstract][Full Text] [Related]
45. Novel IL4I1 Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2023 Jun; 14(6):700-701. PubMed ID: 37312856
[TBL] [Abstract][Full Text] [Related]
46. Novel Lactams as CBL-B Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2023 Jul; 14(7):897-898. PubMed ID: 37465298
[TBL] [Abstract][Full Text] [Related]
47. Novel Diaminopyrimidine Carboxamides as HPK1 Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2023 Jul; 14(7):899-900. PubMed ID: 37465291
[TBL] [Abstract][Full Text] [Related]
48. Novel Lactams as Cbl-b Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2022 Oct; 13(10):1556-1557. PubMed ID: 36267136
[TBL] [Abstract][Full Text] [Related]
49. Novel Exatecan-Derived Topoisomerase-1 Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2024 May; 15(5):579-580. PubMed ID: 38746899
[TBL] [Abstract][Full Text] [Related]
50. 1,2,4-Triazine Derivatives as NLRP3 Inhibitors for Treating Diseases.
Sabnis RW
ACS Med Chem Lett; 2023 May; 14(5):547-548. PubMed ID: 37197471
[TBL] [Abstract][Full Text] [Related]
51. Protease Inhibitors for Treating or Preventing Coronavirus Infection.
Sabnis RW
ACS Med Chem Lett; 2023 Nov; 14(11):1489-1490. PubMed ID: 37974953
[TBL] [Abstract][Full Text] [Related]
52. Novel Haloacethydrazides as AEP Inhibitors for Treating Alzheimer's Disease.
Sabnis RW; Sabnis AR
ACS Med Chem Lett; 2023 Sep; 14(9):1165-1166. PubMed ID: 37736172
[TBL] [Abstract][Full Text] [Related]
53. Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present).
Xu L; Zhang W; Zhuang C
Expert Opin Ther Pat; 2023 Feb; 33(2):101-124. PubMed ID: 36960668
[TBL] [Abstract][Full Text] [Related]
54. Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia.
Sabnis RW
ACS Med Chem Lett; 2023 Aug; 14(8):1043-1044. PubMed ID: 37583831
[TBL] [Abstract][Full Text] [Related]
55. Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia.
Sabnis RW
ACS Med Chem Lett; 2023 Jul; 14(7):891-892. PubMed ID: 37465297
[TBL] [Abstract][Full Text] [Related]
56. Novel Compounds for Preventing SARS-CoV-2 Viral Replication and Treating COVID-19.
Sabnis RW
ACS Med Chem Lett; 2023 Sep; 14(9):1150-1151. PubMed ID: 37736189
[TBL] [Abstract][Full Text] [Related]
57. Novel P2X3 Inhibitors for Treating Neurogenic Disorders.
Sabnis RW
ACS Med Chem Lett; 2023 Sep; 14(9):1146-1147. PubMed ID: 37736194
[TBL] [Abstract][Full Text] [Related]
58. Novel KRAS Inhibitors for Treating Non-Small-Cell Lung Cancer.
Sabnis RW
ACS Med Chem Lett; 2024 Jun; 15(6):773-774. PubMed ID: 38894899
[TBL] [Abstract][Full Text] [Related]
59. Hetero-tricyclic Compounds as KRAS Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2023 Sep; 14(9):1154-1155. PubMed ID: 37736182
[TBL] [Abstract][Full Text] [Related]
60. Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis.
Sabnis RW
ACS Med Chem Lett; 2024 Feb; 15(2):163-164. PubMed ID: 38352824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
